tiprankstipranks
Advertisement
Advertisement
Cathie Wood’s ARK Investment buys 596K shares of Intellia Therapeutics today
PremiumThe FlyCathie Wood’s ARK Investment buys 596K shares of Intellia Therapeutics today
11d ago
Intellia Therapeutics price target raised to $13 from $7 at Baird
Premium
The Fly
Intellia Therapeutics price target raised to $13 from $7 at Baird
11d ago
Intellia Therapeutics price target raised to $58 from $48 at Canaccord
Premium
The Fly
Intellia Therapeutics price target raised to $58 from $48 at Canaccord
11d ago
Intellia Therapeutics price target raised to $30 from $27 at Chardan
PremiumThe FlyIntellia Therapeutics price target raised to $30 from $27 at Chardan
12d ago
Intellia Therapeutics price target raised to $35 from $29 at Leerink
Premium
The Fly
Intellia Therapeutics price target raised to $35 from $29 at Leerink
12d ago
Intellia Therapeutics price target raised to $20 from $19 at BofA
Premium
The Fly
Intellia Therapeutics price target raised to $20 from $19 at BofA
12d ago
Intellia Therapeutics initiates rolling BLA submission for lonvo-z for HAE
PremiumThe FlyIntellia Therapeutics initiates rolling BLA submission for lonvo-z for HAE
12d ago
Intellia Therapeutics: Buy Rating Reiterated on Lonvo-z Phase 3 HAELO Upside Potential; $29 Price Target Maintained
Premium
Ratings
Intellia Therapeutics: Buy Rating Reiterated on Lonvo-z Phase 3 HAELO Upside Potential; $29 Price Target Maintained
12d ago
Intellia to report topline Phase 3 lonvoguran ziclumeran data on 4/27
Premium
The Fly
Intellia to report topline Phase 3 lonvoguran ziclumeran data on 4/27
15d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100